Cysteine Protease Inhibitor Encephalomyelitis by a Small Molecule Arthritis and Experimental Autoimmune the Development of Collagen-Induced andAntigen-Induced Proliferative Responses , Inhibition of Invariant Chain Processing

[1]  Zhaohui Qian,et al.  Ex Vivo Characterization of the Autoimmune T Cell Response in the HLA-DR1 Mouse Model of Collagen-Induced Arthritis Reveals Long-Term Activation of Type II Collagen-Specific Cells and Their Presence in Arthritic Joints1 , 2005, The Journal of Immunology.

[2]  A. Rudensky,et al.  Cathepsin S Controls MHC Class II-Mediated Antigen Presentation by Epithelial Cells In Vivo1 , 2005, The Journal of Immunology.

[3]  P. Christadoss,et al.  Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis1 , 2005, The Journal of Immunology.

[4]  R. Pope,et al.  The role of macrophages in rheumatoid arthritis. , 2005, Current pharmaceutical design.

[5]  C. Watts.  The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules , 2004, Nature Immunology.

[6]  A. Rudensky,et al.  Effect of Decreasing the Affinity of the Class II-Associated Invariant Chain Peptide on the MHC Class II Peptide Repertoire in the Presence or Absence of H-2M1 , 2004, The Journal of Immunology.

[7]  J. R. Somoza,et al.  Peptide ketobenzoxazole inhibitors bound to cathepsin K. , 2003, Biochemistry.

[8]  S. Stevanović,et al.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. , 2003, The Journal of clinical investigation.

[9]  A. Rudensky,et al.  Lysosomal cysteine proteases regulate antigen presentation , 2003, Nature Reviews Immunology.

[10]  E. Weber,et al.  Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Hidde L Ploegh,et al.  Proteolysis and antigen presentation by MHC class II molecules , 2002, Advances in Immunology.

[12]  N. Ishimaru,et al.  Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. , 2002, The Journal of clinical investigation.

[13]  S. Miller,et al.  De Novo Central Nervous System Processing of Myelin Antigen Is Required for the Initiation of Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.

[14]  A. Rudensky,et al.  A Role for Cathepsin L and Cathepsin S in Peptide Generation for MHC Class II Presentation1 , 2002, The Journal of Immunology.

[15]  H. Ploegh,et al.  Specific role for cathepsin S in the generation of antigenic peptides in vivo , 2002, European journal of immunology.

[16]  E. Mellins,et al.  Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles1 , 2001, The Journal of Immunology.

[17]  Martin Deeg,et al.  Cathepsin S and an asparagine‐specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro , 2001, European journal of immunology.

[18]  H. Weiner,et al.  Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. , 2001, The Journal of clinical investigation.

[19]  E. Weber,et al.  Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S , 2001, European journal of immunology.

[20]  P. Ricciardi-Castagnoli,et al.  Developmental plasticity of CNS microglia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Ru,et al.  Azepanone-based inhibitors of human and rat cathepsin K. , 2001, Journal of medicinal chemistry.

[22]  R. Germain,et al.  The transmembrane segment of invariant chain mediates binding to MHC class II molecules in a CLIP‐independent manner , 2001, European journal of immunology.

[23]  J. Palmer,et al.  Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. , 2001, Arthritis and rheumatism.

[24]  H. Ploegh,et al.  Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages , 2000, The Journal of experimental medicine.

[25]  I. Kola,et al.  Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  K. Wucherpfennig,et al.  pH-dependent Peptide Binding Properties of the Type I Diabetes–associated I-Ag7 Molecule: Rapid Release of CLIP at an Endosomal pH , 1999, The Journal of experimental medicine.

[27]  C. Coeshott,et al.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Mehler,et al.  Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. , 1999, Biochemistry.

[29]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[30]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[31]  R. Mitchell,et al.  Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.

[32]  L. Adorini,et al.  Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. , 1998, Journal of immunology.

[33]  A. Rudensky,et al.  Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.

[34]  H. Weiner,et al.  Antigen-driven regulation of experimental autoimmune encephalomyelitis. , 1998, Research in immunology.

[35]  A. Kang,et al.  Collagen-induced arthritis, an animal model of autoimmunity. , 1997, Life sciences.

[36]  C. Peters,et al.  Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism , 1997, The Journal of experimental medicine.

[37]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[38]  T. Johns,et al.  Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis , 1997, Journal of Molecular Medicine.

[39]  K. Gordon,et al.  IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. , 1997, Journal of immunology.

[40]  G. Nepom,et al.  Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions. , 1996, Journal of immunology.

[41]  P. Cresswell,et al.  HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules , 1996, The Journal of experimental medicine.

[42]  H. Rammensee,et al.  The peptide binding motif of the disease associated HLA‐DQ (α 1* 0501, β 1* 0201) molecule , 1996 .

[43]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[44]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[45]  R. Swanborg.  Animal models of human disease : experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease , 1995 .

[46]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[47]  H. Weiner,et al.  Immunologic Mechanisms and Therapy in Multiple Sclerosis , 1995, Immunological reviews.

[48]  A. Waage,et al.  Antigen presentation by human fetal astrocytes with the cooperative effect of microglia or the microglial-derived cytokine IL-1 , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  A Sette,et al.  Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II , 1995, The Journal of experimental medicine.

[50]  P. Cresswell,et al.  In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. , 1994, Immunity.

[51]  G. Loss,et al.  Invariant chain retains MHC class II molecules in the endocytic pathway. , 1993, Journal of immunology.

[52]  Y. Matsumoto,et al.  Immune regulation by brain cells in the central nervous system: microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. , 1992, Immunology.

[53]  K. O. Elliston,et al.  A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.

[54]  C. March,et al.  Molecular cloning of the interleukin-1 beta converting enzyme. , 1992, Science.

[55]  J. Neefjes,et al.  Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. , 1992, The EMBO journal.

[56]  H. Grey,et al.  Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules. , 1990, Journal of Immunology.

[57]  P. Cresswell,et al.  Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens , 1990, The Journal of cell biology.

[58]  H. Kirschke,et al.  Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. , 1989, The Biochemical journal.

[59]  H. Luthra,et al.  Type II collagen-induced arthritis in mice. IV. Variations in immunogenetic regulation provide evidence for multiple arthritogenic epitopes on the collagen molecule. , 1985, Journal of immunology.

[60]  S. Sriram,et al.  Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 , 1985, The Journal of experimental medicine.

[61]  I. Egorov,et al.  Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. , 1985, Journal of immunology.

[62]  R. Schwartz.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. , 1985, Annual review of immunology.

[63]  H. Luthra,et al.  Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates , 1981, The Journal of experimental medicine.

[64]  C B Pettinelli,et al.  Adoptive transfer of experimental allergic encephalomyelitis in mice after in vitro activation of lymph node cells by specific antigen. Abstr. , 1981 .